Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides
Investigative Ophthalmology & Visual Science2017Vol. 58(5), pp. 2578–2578
Citations Over TimeTop 10% of 2017 papers
Felicity de Cogan, Lisa J. Hill, A.C. Lynch, Peter Morgan-Warren, Judith Lechner, Matthew R. Berwick, Anna F. A. Peacock, Mei Chen, Robert A. H. Scott, Heping Xu, Ann Logan
Abstract
CPPs are nontoxic to ocular cells and can be used to deliver therapeutically relevant doses of ranibizumab and bevacizumab by eye drop to the posterior segment of mouse, rat, and pig eyes. The CPP + anti-VEGF drug complexes were cleared from the retina within 24 hours, suggesting a daily eye drop dosing regimen. Daily, topically delivered anti-VEGF with CPP was as efficacious as a single ivit injection of anti-VEGF in reducing areas of CNV in vivo.
Related Papers
- → Clinical Experience of Switching Anti-VEGF Therapy from Ranibizumab to Aflibercept in Age-Related Choroidal Neovascularization(2016)9 cited
- → Non-Responders to Intravitreal Ranibizumab in Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration(2016)6 cited
- Recent advances in intravitreal injection of ranibizumab for myopic choroidal neovascularization(2014)
- → A systematic review of clinical application of ranibizumab in wet age-related macular degeneration(2011)
- → INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY(2015)